Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
Jui-Ming LiuYueh-Ping LiuHeng-Chang ChuangChun-Te WuYu-Li SuRen-Jun HsuPublished in: PloS one (2020)
The use of ADT in patients with prostate cancer may increase the risk of subsequently developing hematologic disorders.
Keyphrases